Advertisement

THE INCREMENTAL VALUE OF AMYLOID PET VERSUS CSF BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (INDIA–FBB STUDY)

      Amyloid PET and CSF Aβ42 have demonstrated analytical and clinical validity, but their comparative clinical utility is unclear. The aim of this study is to compare the incremental diagnostic value of [18F]-Florbetaben PET and CSF markers (Aβ42, tau and ph-tau) in patients with cognitive impairment.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'